InMed Pharmaceuticals is pleased to welcome the BayMedica team following the acquisition in October 2021.
Meet Chris Meiering, our VP of Commercial Operations. Chris talks about the unique start to his career in pet nutrition and how he got into the business of developing rare cannabinoids for the health and wellness sector.
Chris earned his PhD in microbiology, specializing in molecular virology, from the University of Washington and performed his post doctoral research at Stanford University.
Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,
A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8
© Copyright 2025 InMed Pharmaceuticals Inc.
"*" indicates required fields